World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
23652
World Ranking
16164
National Ranking
8133

Ronald A. Lubet publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ronald A. Lubet sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 464 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ronald A. Lubet D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald A. Lubet sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ronald A. Lubet is affiliated with the National Institutes of Health in the United States. Their research spans multiple interconnected fields, primarily in medicine, immunology and microbiology, and biochemistry, genetics, and molecular biology. The main focus of their work includes immunotherapy, cancer immunology, and molecular mechanisms related to cancer progression and treatment.

Their scholarly output includes studies published in journals such as Cancer Prevention Research, Cancer Research, Advanced Science, Frontiers in Immunology, and Communications Biology. Their frequent publication venues indicate a concentration on cancer prevention and treatment research.

Among their recent papers are:

  • Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer, 2022, Advanced Science
  • Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention, 2021, Frontiers in Immunology
  • Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA, 2021, Communications Biology
  • Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention, 2023, npj Precision Oncology
  • Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat, 2021, Cancer Prevention Research

Lubet's research is situated within several subfields such as immunology, oncology, pulmonary and respiratory medicine, molecular biology, and surgery. These subfields reflect a multidisciplinary approach to cancer and immune system-related diseases.

Their main topics of study cover:

  • Immunotherapy and Immune Responses
  • Immune cells in cancer
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Research and Treatments
  • Vaccines and immunoinformatics approaches
  • T-cell and B-cell Immunology

Frequent collaborators within their research network include Shizuko Sei, Robert H. Shoemaker, Yian Wang, Katie Palen, and Bryon D. Johnson, reflecting ongoing partnerships in producing research outputs primarily focused on cancer biology and immunotherapy.

Best Publications

  • Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

    Toshihiko Kawamori;Ronald Lubet;Vernon E. Steele;Gary J. Kelloff

  • Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat.

    Ronald A. Lubet;Richard T. Mayer;John W. Cameron;Raymond W. Nims

  • The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

    Russell F. Jacoby;Karen Seibert;Carolyn E. Cole;Gary Kelloff

  • Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis

    Bandaru S. Reddy;Yoshinobu Hirose;Ronald Lubet;Vernon Steele

  • Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

    Gary J. Kelloff;James A. Crowell;Vernon E. Steele;Ronald A. Lubet

  • Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

    Susan M. Fischer;Herng-Hsang Lo;Gary B. Gordon;Karen Seibert

  • Expression of CYP1A1 Gene in Patients With Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas

    Theodore L. McLemore;Steven Adelberg;Mark C. Liu;Noreen A. McMahon

  • Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam

    Russell F. Jacoby;David J. Marshall;Michael A. Newton;Kristian Novakovic

  • Lipoxygenase inhibitors as potential cancer chemopreventives.

    Vernon E. Steele;Cathy A. Holmes;Ernest T. Hawk;Levy Kopelovich

  • Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats

    Clinton J. Grubbs;Ronald A. Lubet;Alane T. Koki;Kathleen M. Leahy

  • Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.

    Michael A. Pereira;Clinton J. Grubbs;Leta H. Barnes;Hong Li

  • Chemopreventive Drug Development: Perspectives and Progress

    Gary J. Kelloff;Charles W. Boone;James A. Crowell;Vernon E. Steele

  • Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 AND 2B, respectively, in the rat and mouse

    Pratibha V. Nerurkar;Sang S. Park;Paul E. Thomas;Raymond W. Nims

  • Strategy and planning for chemopreventive drug development: Clinical development plans II

    Gary J. Kelloff;James A. Crowell;Ernest T. Hawk;Vernon E. Steele

  • Measurement of cytochrome P-450 dependent dealkylation of alkoxy-phenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicumarol

    Ronald A. Lubet;Raymond W. Nims;Richard T. Mayer;John W. Cameron

  • Chemoprevention of colon carcinogenesis by dietary perillyl alcohol

    Bandaru S. Reddy;C-X. Wang;Hanan Samaha;Ronald Lubet

  • Enhancement of experimental colon cancer by genistein

    Chinthalapally V. Rao;Chung Xiou Wang;Barbara Simi;Ronald Lubet

  • Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program

    V. E. Steele;R. C. Moon;R. A. Lubet;C. J. Grubbs

  • Mechanistic considerations in chemopreventive drug development.

    Gary J. Kelloff;Charles W. Boone;Vernon E. Steele;Judith R. Fay

  • Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.

    Russell F. Jacoby;Carolyn E. Cole;Kendra Tutsch;Michael A. Newton

Frequent Co-Authors

Vernon E. Steele
Vernon E. Steele National Institutes of Health
Ming You
Ming You Medical College of Wisconsin
Gary J. Kelloff
Gary J. Kelloff National Institutes of Health
Ann M. Bode
Ann M. Bode University of Minnesota
Zigang Dong
Zigang Dong University of Minnesota
Jerrold M. Ward
Jerrold M. Ward National Institutes of Health
Chinthalapally V. Rao
Chinthalapally V. Rao University of Oklahoma Health Sciences Center
Feng Zhu
Feng Zhu Zhejiang University
Robert H. Shoemaker
Robert H. Shoemaker National Institutes of Health
Paul E. Thomas
Paul E. Thomas Rutgers, The State University of New Jersey

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens up a variety of related online degrees and career pathways. Beyond the traditional MD route, healthcare administration is a growing field for those interested in the business and organizational side of hospitals and clinics. Earning a health care administration online degree can be a flexible, affordable entry point, preparing graduates for management roles in healthcare settings.

For those looking to advance their credentials even further, the most affordable mha programs offer focused training in leadership, policy, and strategic decision-making. Similarly, nurses seeking top-level roles can consider the cheapest dnp program, which opens doors to advanced clinical practice, administration, or teaching.

Another promising pathway is pharmacy, where accelerated and flexible options like a 3 year online pharmd program help meet the demand for skilled pharmacists. These alternative and supplementary degrees are great for students seeking impactful healthcare careers without attending medical school.

Best Scientists Citing Ronald A. Lubet

Trending Scientists

Recently Published Articles